Does atherosclerosis come in different flavors? A longstanding rule in atherosclerosis
pathology is that plaques develop along the same pattern regardless of the dominant
risk factor(s) driving the process. Thus atherosclerosis in hypercholesterolemia cannot
be distinguished pathologically from atherosclerosis in diabetes with high triglycerides
and low HDL, and atherosclerosis in a patient with lupus looks pretty much the same.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical LipidologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence of heterozygous familial hypercholesterolaemia and combined hyperlipidaemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.J Clin Lipidol. 2019; 13: 502-508
- Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia.J Clin Lipidol. 2018; 12: 33-43
- Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N Engl J Med. 2019; 380: 11-22
- The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: a secondary analysis of a randomized clinical trial.J Clin Lipidol. 2018; 12: 937-947
- Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Cholesterol Guidelines get apoB right?.J Clin Lipidol. 2019; 13: 360-366
- Elevated apolipoprotein B as a risk enhancing factor in the 2018 Cholesterol Guidelines.J Clin Lipidol. 2019; 13: 356-359
- Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A Scientific Statement from the National Lipid Association.J Clin Lipidol. 2019; 13: 374-392
- The STatin Adverse Treatment Experience (STATE) survey: experience of patients reporting side effects of statin therapy.J Clin Lipidol. 2019; 13: 415-424
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc. on behalf of National Lipid Association.
